AMLXAmylyx Pharmaceuticals, Inc.

Nasdaq amylyx.com


$ 2.08 $ 0.08 (4 %)    

Friday, 03-May-2024 12:20:20 EDT
QQQ $ 435.29 $ 2.97 (0.69 %)
DIA $ 386.41 $ -0.33 (-0.09 %)
SPY $ 510.92 $ 0.39 (0.08 %)
TLT $ 89.66 $ -0.45 (-0.5 %)
GLD $ 212.49 $ -0.93 (-0.44 %)
$ 2
$ 2.05
$ 2.07 x 200
$ 2.09 x 400
$ 2.00 - $ 2.12
$ 1.70 - $ 30.50
1,911,403
na
139.98M
$ 0.93
$ 2.84
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-22-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-13-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 baird-maintains-neutral-on-amylyx-pharma-lowers-price-target-to-3

Baird analyst Joel Beatty maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and lowers the price target from $4 to $3.

 hc-wainwright--co-reiterates-buy-on-amylyx-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

 amylyx-pharmaceuticals-investigational-drug-shows-improved-pancreatic-function-in-patients-with-inherited-disorder

Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, ...

 amylyx-pharmaceuticals-announces-interim-data-from-phase-2-helios-clinical-trial-of-amx0035-in-adults-with-wolfram-syndrome

- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glyc...

 amylyx-pharmaceuticals-to-host-virtual-webcast-to-discuss-interim-data-from-phase-2-helios-study-of-amx0035-in-wolfram-syndrome-on-april-10-2024

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the Company will host a ...

 hc-wainwright--co-maintains-buy-on-amylyx-pharma-maintains-8-price-target

HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

 amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrioalbrioza-from-the-market

Relyvrio/Albrioza will no longer be available for new patients as of today; Patients currently on therapy in the U.S. and Canad...

 cns-disorder-focused-seelos-therapeutics-plunges-to-52-week-low---heres-why

Seelos Therapeutics updates Phase 2/3 HEALEY ALS trial with SLS-005, showing potential efficacy in subgroup analysis. Explore t...

 hc-wainwright--co-maintains-buy-on-amylyx-pharma-lowers-price-target-to-8

HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and lowers the price target fro...

 goldman-sachs-downgrades-amylyx-pharma-to-neutral-lowers-price-target-to-4

Goldman Sachs analyst Chris Shibutani downgrades Amylyx Pharma (NASDAQ:AMLX) from Buy to Neutral and lowers the price target...

 leerink-partners-downgrades-amylyx-pharma-to-market-perform

Leerink Partners analyst Marc Goodman downgrades Amylyx Pharma (NASDAQ:AMLX) from Outperform to Market Perform.

 baird-downgrades-amylyx-pharma-to-neutral-lowers-price-target-to-4

Baird analyst Joel Beatty downgrades Amylyx Pharma (NASDAQ:AMLX) from Outperform to Neutral and lowers the price target from...

 dow-gains-over-100-points-aersale-shares-plunge-after-q4-results

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dipping around 0.5% on Friday. The Dow traded up...

 stocks-fall-as-chipmakers-retreat-from-highs-bitcoin-pulls-back-after-70000-gold-rises-to-2200-whats-driving-markets-friday

The stock market is navigating a mixed closing session this week, with the S&P 500 and Nasdaq 100 struggling to stave off a...

 evercore-isi-group-downgrades-amylyx-pharma-to-in-line

Evercore ISI Group analyst Umer Raffat downgrades Amylyx Pharma (NASDAQ:AMLX) from Outperform to In-Line.

 why-marvell-technology-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quart...

 crude-oil-falls-over-1-willdan-group-shares-spike-higher

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 80 points on Friday. The Dow traded u...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION